ArticleBreast cancer (Tokyo, Japan)2026

Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).

Shigenori E Nagai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.